Acadia Pharmaceuticals Stock News

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Equities research analysts at SVB Leerink lifted their FY2021 EPS estimates for shares of ACADIA Pharmaceuticals in a report issued on Monday, December 6th. SVB Leerink analyst M. Goodman now expects that the biopharmaceutical company will post earnings per share of ($1.03) for the year, up from their prior forecast []

ACADIA Pharmaceuticals (NASDAQ:ACAD) had its price target upped by research analysts at Morgan Stanley from $21.00 to $24.00 in a research report issued on Tuesday, Price Targets.com reports. The brokerage presently has an equal weight rating on the biopharmaceutical companys stock. Morgan Stanleys price objective suggests a potential upside of 10.19% from the stocks current [] The post ACADIA Pharmaceuticals (NASDAQ:ACAD) PT Raised to $24.00 appeared first on ETF Daily News .

ACADIA Pharmaceuticals (NASDAQ:ACAD) had its target price raised by equities research analysts at Cantor Fitzgerald from $27.00 to $31.00 in a report issued on Tuesday, The Fly reports. The firm presently has an overweight rating on the biopharmaceutical companys stock. Cantor Fitzgeralds price target indicates a potential upside of 42.33% from the companys current price. []

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Analysts at SVB Leerink lowered their FY2024 earnings estimates for ACADIA Pharmaceuticals in a research note issued on Monday, December 6th. SVB Leerink analyst M. Goodman now forecasts that the biopharmaceutical company will post earnings of $1.30 per share for the year, down from their previous forecast of $1.35. A []

Company now well-positioned to seek FDA approval for trofinetide Related Stocks: ACAD , AVXL , RARE , GWPH , NVS ,

Acadia Pharmaceuticals Inc. ( ACAD , Financial) investors finally got some good news this week when the biopharma announced positive test results for its treatment for a rare neurological condition.

All of these names are down for a reason, but only some of them are down for a reason that's apt to last.

Acadia's (ACAD) study results and other pipeline updates have been the biotech sector's few key highlights during the past week.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)s stock price gapped down before the market opened on Monday . The stock had previously closed at $19.94, but opened at $18.65. ACADIA Pharmaceuticals shares last traded at $19.00, with a volume of 748 shares changing hands. ACAD has been the subject of a number of recent research reports. JMP Securities []

ACADIA Pharmaceuticals (NASDAQ:ACAD) had its price objective hoisted by JMP Securities from $35.00 to $39.00 in a report released on Tuesday morning, Price Targets.com reports. The firm currently has a market outperform rating on the biopharmaceutical companys stock. A number of other analysts also recently commented on the company. Mizuho upped their price objective on []

ACADIA Pharmaceuticals (NASDAQ:ACAD) had its price target upped by Citigroup from $25.00 to $28.00 in a research note published on Tuesday, The Fly reports. They currently have a neutral rating on the biopharmaceutical companys stock. ACAD has been the topic of a number of other reports. Morgan Stanley cut shares of ACADIA Pharmaceuticals from an []

Acadia reported solid earnings for Q3, 2021 despite COVID-19 headwind lashing its Parkinson's Disease Psychosis [PDP] earnings. Acadia's completed Type A Meeting with the FDA has opened the door for a

ACADIA's (ACAD) phase III study, evaluating the efficacy and safety of trofinetide in patients with Rett syndrome, meets co-primary endpoints. Shares rise.

Over the past 3 months, 7 analysts have published their opinion on ACADIA Pharmaceuticals (NASDAQ: ACAD ) stock. These analysts

While markets are cautiously optimistic on the Omicron variant, these health care stocks are still hard at work.